Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Centrally-acting non-narcotic antitussive, chemically related to codeine but devoid of central depressant effects (AEMPS 2014, Ida 1997).
Chemically similar to dextromethorphan (Shin 2011).
Administered orally 3 times a day.
A product which has very few bibliographical references.
Since the last update, we have not found published data on its excretion in breast milk.
Its use is authorized in infants from 6 months of age.
Given its lack of sedative effects, use at a sufficient minimum dose and for non-prolonged periods would have low risk during breastfeeding.
As there is less published experience than with other drugs from the same group, safer known alternatives may be preferable during the neonatal period and in case of prematurity.